Pre-Market Top Loser: GNCA Genocea Biosciences (NASDAQ) 13 Feb 2026: liquidity flag

GNCA stock opened the pre-market session on 13 Feb 2026 at USD 0.0001, down about 97.44% from the prior close. This sharp fall places Genocea Biosciences, Inc. (GNCA) among pre-market top losers on the NASDAQ in the United States. Volume was light at 30,268 shares versus a 50-day average of 80,568. Investors should note the stock’s near-zero market cap reading and Chapter 11 history as key drivers of extreme volatility.

GNCA stock market snapshot and session moves

GNCA stock trades on the NASDAQ in the United States at USD 0.0001 pre-market on 13 Feb 2026. Intraday range shows a day low and day high of USD 0.0001, with an open of USD 0.0007 and prior close USD 0.0039. Average volume is 80,568; today’s volume is 30,268, a relative volume of 0.38. The one-day change reads -97.44%, reflecting either a corporate event, quote adjustment, or delisting/restructuring pressure.

Why GNCA stock is a top loser: catalysts and news links

The immediate driver of GNCA stock’s plunge is company distress and reduced investor confidence after Genocea’s Chapter 11 filing in July 2022 and sparse updates since. The biotech sector remains watched, but Genocea’s clinical pipeline news has been inactive and liquidity is constrained. For context on peer and competitor movement, see a recent competitor comparison and benchmark analysis from MarketBeat and Investing.com, which reference GNCA among OTC/NASDAQ small-cap peers source source.

GNCA stock financials, valuation and key metrics

Genocea’s trailing metrics show very low market cap and no reported EPS. Key ratios include a current ratio of 2.24, cash per share USD 0.54, and a book value per share of USD 0.39. Price averages sit at 50-day USD 0.0047 and 200-day USD 0.1146. Enterprise value reads negative due to net cash and negligible equity value. These metrics explain heavy valuation compression versus biotech peers.

Technical and trading data for GNCA stock

Technically, GNCA stock shows collapse from a year high of USD 1.45 to a year low of USD 0.0001. Short-term momentum is negative: 1-day change -96.77%, 3-month change -98.31%, and 1-year change -99.99%. Low free float and infrequent trading create wide spreads and thin liquidity. Traders should expect erratic quotes and price gaps during U.S. pre-market and regular hours.

Meyka AI grade and GNCA stock risk assessment

Meyka AI rates GNCA with a score out of 100: Score: 62.46 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. The grade reflects the firm’s remaining assets and cash per share but flags liquidity, limited trading, and operational uncertainty. These grades are informational only and not financial advice.

GNCA stock outlook, catalysts and near-term forecast

Near-term catalysts would be a corporate restructuring update, debt resolution, or a clear asset sale timeline. Absent those, GNCA stock will likely remain range-bound at penny fractions. Sector performance in Healthcare and Biotechnology may lift interest, but Genocea-specific news is the main driver. For deeper platform data see the Meyka GNCA summary page Meyka GNCA page.

Final Thoughts

Key takeaways on GNCA stock: Genocea Biosciences, Inc. (GNCA) trades at USD 0.0001 pre-market on 13 Feb 2026 after a ~97% one-day drop. Financially, the company shows cash per share USD 0.54 and a current ratio of 2.24, but near-zero market value and Chapter 11 legacy create severe liquidity and execution risk. Meyka AI’s forecast model projects a short-term reference level of USD 0.0003, versus the current USD 0.0001, implying a model-based upside of +200.00% from today’s quote. That projection is model-based and not a guarantee. Investors should treat GNCA stock as highly speculative, expect wide spreads and potential quote anomalies, and monitor official filings and NASDAQ status closely. Meyka AI, an AI-powered market analysis platform, recommends priority on verified corporate updates before allocating capital.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.